The US National Institute of Health (NIH) has advised to use Truvada from Gilead Sciences, Inc. (NASDAQ-GILD) as a possible prevention against HIV for people who are at high risk contracting the virus. The American Health Organization claims to have found a “substantial contribution” in preventing this disease. Having the law on affordable care in mind, the company plans to extend coverage of this preventive care. Gilead Sciences, Inc. (NASDAQ-GILD) has also recently established cooperation with Precision BioSciences and Gadeta B.V. to research and develop new drugs and therapies. These facts have attracted private investors and multinational investment corporations who increased their interest in Gilead Sciences, Inc. (NASDAQ-GILD) shares, which at the start of the trading day on May 16, 2019 reached the value of US$66.05 per share with a daily boost of + 1.15% of its price.
Gilead Sciences, Inc. (NASDAQ-GILD) is an American bio-pharmaceutical company that manufactures, develops and markets medical care medicines. The company’s name and logo refers to the Galád Balm, inspired by Lanford Wilson’s play from 1965, the underworld and adventurous patron saint of the café of the same name. Gilead Sciences, Inc. (NASDAQ-GILD) was founded more than thirty years ago in 1987 in Foster City, California, where it also has its headquarters. The company has offices in more than 30 countries around the world in North America, Europe and Australia. Since its establishment, the company has mainly focused on the research and production of antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C and influenza. In 2006, Gilead Sciences, Inc. (NASDAQ-GILD) bought two companies that developed drugs to treat patients with lung disease. Currently, the company manufactures a range of commercially available products, especially hepatitis C drugs (Harvoni and Sovaldi).
Gilead Sciences, Inc. (NASDAQ-GILD) also reported that, with the right use of Truvada, which is used to prevent contracting HIV, it is very effective to treat new infections. The drug has contributed to lowering the number of new HIV cases to the lowest levels since the outbreak in the 1980s. The company also recently released the economic outcomes for the third quarter of 2018, with the United States accounting for the most revenue, with US$4.1 billion and Europe with US$873 million. In its press release Gilead Sciences, Inc. (NASDAQ-GILD) also reported that it has collaborated with the biotechnology company Precision BioSciences to develop therapies aimed at eliminating HIV virus using the ARCUS genome modification platform. The company also has a strategic collaboration with Gadeta B.V. in the development of a new gamma-delta T cell receptor therapy used for treating various types of cancers. The company currently employs approximately 10,000 core workers.
Gilead Sciences, Inc. (NASDAQ-GILD) also pays its shareholders an attractive, quarterly paid dividends. The dividend yield is currently 3.81% p.a. and the dividend amount was approved by the Company’s General Meeting at US$2.52 per share. Currently, shareholders can also look forward to the payment of a dividend with the so-called Ex-Dividend Date set for 13 June, 2019 and the Pay Date set for 27 June, 2019. The company has now become very attractive to private investors and multinational corporations thanks to the recommendation of NIH to use its Truvada drug but also because of the company’s cooperation with other companies and the currently known dividend payout date. According to analysts and financial strategists, a share price increase can be expected over the medium term, with the average target price set at US$80.47 per share.